STOCK TITAN

Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Exact Sciences EVP of Human Resources Sarah Condella reported several equity transactions in company stock. She exercised stock options covering 3,900 shares of Common Stock at an exercise price of $5.03 per share, increasing her direct holdings before related tax withholding.

To cover tax obligations from this option exercise, 1,913 shares of Common Stock were retained by Exact Sciences at $103.38 per share, leaving her with 131,121 shares held directly and 6,368 shares held indirectly in a 401(k) plan. Footnotes note that the Form 4 covers 137,489 shares of Common Stock in total and that she also holds an additional 71,243 vested and unvested options and restricted stock units.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Condella Sarah

(Last) (First) (Middle)
C/O EXACT SCIENCES CORP.
5505 ENDEAVOR LANE

(Street)
MADISON WI 53719

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Human Resources
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/27/2026 M 3,900 A $5.03 133,034 D
Common Stock 02/27/2026 F(1) 1,913 D $103.38 131,121(2) D
Common Stock 6,368 I Held in 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $5.03 02/27/2026 M 3,900 (3) (3) Common Stock 3,900 $0 0 D
Explanation of Responses:
1. Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the exercise of certain stock options.
2. In addition to the shares of Common Stock reported on this Form 4, which total 137,489 shares, Ms. Condella also holds, in the aggregate, an additional 71,243 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
3. These options vested and became exercisable in full on February 28, 2020.
/s/ Sarah Condella by Mark Busch, attorney-in- fact 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did EXACT SCIENCES (EXAS) report for Sarah Condella?

EVP Sarah Condella exercised stock options for 3,900 shares of Common Stock at $5.03 per share. To satisfy taxes, 1,913 shares were retained by Exact Sciences, leaving her with 131,121 shares directly and 6,368 shares indirectly in a 401(k) plan.

Were Sarah Condella’s EXAS transactions open-market stock purchases or sales?

The reported activity reflects an option exercise and tax withholding, not open-market trades. Condella exercised stock options into 3,900 shares, and 1,913 shares were withheld by Exact Sciences to cover tax obligations, a common administrative mechanism for equity compensation.

How many EXACT SCIENCES shares does Sarah Condella hold after these Form 4 transactions?

After the transactions, Condella holds 131,121 shares of Common Stock directly and 6,368 shares indirectly through a 401(k) plan. Footnotes state this Form 4 covers 137,489 Common shares in total, excluding additional options and restricted stock units she also holds.

What portion of Sarah Condella’s EXAS shares was used for tax withholding?

A total of 1,913 shares of Common Stock were retained by Exact Sciences for tax withholding related to her option exercise. These shares were valued at $103.38 each for withholding purposes, according to the disclosure and accompanying explanatory footnote on the Form 4.

Does Sarah Condella hold additional EXAS equity beyond the shares listed on this Form 4?

Yes. Footnotes explain that besides the 137,489 shares reported, she holds an additional 71,243 vested and unvested stock options and restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Exact Sciences Common Stock in the future.

When did the EXAS stock options exercised by Sarah Condella become fully vested?

The options exercised in this Form 4 became fully vested and exercisable on February 28, 2020. This means her right to convert those options into shares of Common Stock was fully established as of that date, prior to the February 27, 2026 exercise transaction.
Exact Sciences Corp

NASDAQ:EXAS

EXAS Rankings

EXAS Latest News

EXAS Latest SEC Filings

EXAS Stock Data

19.73B
186.79M
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON